Effects of a single dose and short-term captopril treatment on some pressor and depressor humoral factors in healthy subjects

Zacharieva, Sabina; Orbetzova, Maria; Angelova-Gateva, P; K, Andonova

doi:10.1016/0952-3278(95)90059-4

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can also prevent the platelet aggregation induced by arachidonic acid or adenosine diphosphate, thus inhibiting the formation of thrombus [ 18 ]. Studies on healthy volunteers [ 19 ] and patients [ 20 ] showed that indobufen effectively inhibited thromboxane A2 formation, but had little effect on prostacycline, which was different from aspirin. These results theoretically indicated that indobufen had higher selectivity for platelet inhibition and better gastrointestinal tolerance, which was further confirmed by an endoscopic study [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry

Dai,

Liu,

Yang

et al. 2024

BMC Med

View full text Add to dashboard Cite

Background Indobufen is widely used in patients with aspirin intolerance in East Asia. The OPTION trial launched by our cardiac center examined the performance of indobufen based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). However, the vast majority of patients with acute coronary syndrome (ACS) and aspirin intolerance were excluded. We aimed to explore this question in a real-world population. Methods Patients enrolled in the ASPIRATION registry were grouped according to the DAPT strategy that they received after PCI. The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. Propensity score matching (PSM) was adopted for confounder adjustment. Results A total of 7135 patients were reviewed. After one-year follow-up, the indobufen group was associated with the same risk of MACCE versus the aspirin group after PSM (6.5% vs. 6.5%, hazard ratio [HR] = 0.99, 95% confidence interval [CI] = 0.65 to 1.52, P = 0.978). However, BARC type 2, 3, or 5 bleeding was significantly reduced (3.0% vs. 11.9%, HR = 0.24, 95% CI = 0.15 to 0.40, P < 0.001). These results were generally consistent across different subgroups including aspirin intolerance, except that indobufen appeared to increase the risk of MACCE in patients with ACS. Conclusions Indobufen shared the same risk of MACCE but a lower risk of bleeding after PCI versus aspirin from a real-world perspective. Due to the observational nature of the current analysis, future studies are still warranted to further evaluate the efficacy of indobufen based DAPT, especially in patients with ACS. Trial registration Chinese Clinical Trial Register (https://www.chictr.org.cn); Number: ChiCTR2300067274.

show abstract